Ceskaa Market Research (http://www.ceskaa.com/shop/new-research-2/global-market-for-erythropoietin-report-2015-2020/) has announced the addition of the Erythropoietin Market: 2015-2020 report to their offering.

The global erythropoietin drug market has been primarily dominated by biologics in the developed countries and by biosimilar in the developing countries. The North America region dominates the global erythropoietin drug market followed by Europe and Asia-Pacific.

The major players in the biologic erythropoietin drug market are, Amgen, Inc., Johnson & Johnson and Hoffmann-LA Roche. Sandoz (subsidiary of Novartis International AG), Hospira (subsidiary of Pfizer, Inc.), Biocon, Biosidus, 3SBio, are some of the major biosimilar players across regions.

This market research report explain current market for erythropoietin drugs in terms of value. The report also highlights the major drivers and challenges, including their profiles related to erythropoietin drugs.

The global market for erythropoietin drugs has been growing at a CAGR (2015 to 2020) of 1.0% driven by the increasing cases of anemia particularly in kidney diseases and cancer globally.

The global erythropoietin drugs market is expected to grow from $7.0 billion in 2014 to $7.4 billion in 2015 at a year-on-year (YOY) growth rate of 5.1%. In addition, the market is expected to grow at a five-year CAGR (2015 to 2020) of 1.0%, to reach $7.8 billion in 2020.


For more information visit: http://www.ceskaa.com/shop/new-research-2/global-market-for-erythropoietin-report-2015-2020/
Contact:
Tisha Thomas
Email: [email protected]
Phone: +1 973-805-7440
Website: https://ceskaa.com/
Source: Ceskaa Research